D-Wave vs. Quantum Computing: Which Stock is Truly Worth the Hype?

D-Wave (QBTS) is showing accelerating commercial traction with >100 revenue customers and system sales (including a €10m Advantage2 contract), Q3 revenue doubling to $3.7m, GAAP gross margin of 71.4% (non-GAAP 77.7%) and year-to-date GAAP margin rising to 84.8%; cash surged to $836.2m, but Q3 net loss widened to $140.8m largely from $121.9m non-cash warrant charges and adjusted EBITDA loss was $20.6m. Quantum Computing Inc. (QUBT) raised over $1.5bn in 2025 (including $500m in Q3 and $750m after), reported Q3 revenue of $384k while Q3 operating costs nearly doubled to $10.5m as Fab1 produces TFLN chips and DIRAC-3 begins initial cloud revenues; Zacks ranks both at Hold, QBTS has outperformed in the past six months, while analyst short-term targets imply meaningful upside for both names.

Analysis

Market structure: D-Wave (QBTS) is moving from R&D into product-led revenue with >100 paying customers and system sales (e.g., €10m Italy deal) driving GAAP gross margins >70% and cash of ~$836m — that strengthens pricing power for system sales and services and favors vendors of quantum annealing and hybrid optimization. Quantum Computing, Inc. (QUBT) benefits indirectly from a $1.5bn capital runway to scale TFLN fabs, but rising opex and slower revenue ($0.384m Q3) imply customers and partners will capture most near-term upside while equity holders face dilution risk. Cross-asset: stronger QBTS funding compresses credit premia for high‑growth tech, reduces corporate credit stress in the niche, and keeps equity implied vols elevated (20–40%+); commodity/FX impacts are negligible outside USD funding flows for Fab 2 capex.

Risk assessment: Tail risks include (1) large warrant-induced dilution or repeat non-cash charges for QBTS (>$100m buckets) that can swing EPS and shares, (2) Fab2 execution failure for QUBT that could burn >$500m over 12–24 months, and (3) government procurement reversals or security restrictions on foreign deployments. Immediate (days) risk: idiosyncratic headline swings; short-term (weeks/months): quarterly bookings, warrant exercises, and QUBT opex cadence; long-term (quarters/years): commercialization of Fab2, gated by supply-chain and qualified-customer ramp. Hidden dependencies: customer concentration among Global2000, vendor readiness for systems integration, and government contracting cycles that can accelerate or stall revenue recognition.

Trade implications: Favor a measured long in QBTS given current evidence of product-market fit — allocate 1–3% portfolio positions and scale into confirmed recurring bookings or additional system purchases within 9–12 months; use covered-call overlays to monetize if volatility drops. Use a relative-value pair: long QBTS / short QUBT (dollar-neutral, 6–12 months) to express execution/quality divergence while hedging macro beta; if QUBT posts >50% QoQ revenue growth or Fab2 metrology milestones, reduce short. For asymmetric exposure to QUBT optionality, buy a small Jan‑2027 QUBT call spread (size 0.5% portfolio) financed by selling short-dated OTM premium to cap cost.

Contrarian angles: Consensus understates QUBT’s optionality from TFLN if Fab2 scales and telecom/AI customers pay premium ASPs — the market may be too negative on cash burn today. Conversely, QBTS’s stock may be underestimating warrant overhang and recurring non-cash charges; a single large warrant realization could erase near-term gains. Historical parallels: hardware cycles (GPUs, FPGAs) saw long lags between capital raise and durable revenue — expect 12–36 months of bifurcated outcomes. Unintended consequence: aggressive QUBT expansion could trigger a funding-driven slump if Fab2 delays force down-rounds, making the short leg of the pair trade the bigger asymmetry.

Key Decisions for Investors

• Establish a 2–3% long position in QBTS common equity sized to portfolio risk tolerance; target $37 (≈+65%) within 9–12 months based on analyst-implied upside, trim half at +30% and set a hard stop-loss at -25% ($~17) to limit dilution/warrant shock exposure.
• Construct a dollar‑neutral pair trade: long QBTS 2% vs short QUBT 1.5% (or equivalent notional via swaps/borrows) over a 6–12 month horizon to express relative execution; unwind or cut short if QUBT posts >50% QoQ revenue growth or announces validated Fab2 manufacturing milestones.
• Buy an asymmetric option on QUBT: Jan‑2027 call spread (buy low strike, sell higher strike to cap cost) sized ~0.5% of portfolio to capture upside from Fab2 commercialization; finance by selling 1–3 month OTM calls on QUBT to reduce net premium, but close if QUBT opex growth >30% QoQ.
• Monitor specific triggers within 60–90 days: QBTS warrant exercise schedule and cash balance (reduce exposure by 50% if cash declines >20% or additional non-cash warrant charges >$100m recur), and QUBT Fab2 timeline updates (pause shorts if Fab2 achieves production milestones ahead of schedule).